Nightstarx closes $35M series B round, sets sights on choroideremia trial

DUBLIN – UK gene therapy firm Nightstarx Ltd. took in $35 million in a series B round to move its lead program in choroideremia into a pivotal trial next year and to move two other programs in inherited retinal diseases into the clinic by 2017.